Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.49 |
| ▸ | TACR3 | P29371 | 3/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | MTTP | P55157 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448206 | 0.81 | MTTP (0.52) | TACR1TACR3MTTPRORC | |
| SCHEMBL4448204 | 0.81 | MTTP (0.52) | TACR1TACR3MTTPRORC | |
| SCHEMBL4450456 | 0.79 | NPC1 (0.64) | TACR3 | |
| SCHEMBL4448618 | 0.79 | TAS1R3 (0.46) | TACR3ULK1MTTPCYP1A2CYP3A4 | |
| SCHEMBL4444765 | 0.77 | S1PR3 (0.56) | TACR3CYP1A2CYP3A4TSHR | |
| SCHEMBL4447357 | 0.77 | ANPEP (0.46) | MTTPRORC | |
| SCHEMBL4446727 | 0.77 | ANPEP (0.46) | MTTPRORC | |
| SCHEMBL4446731 | 0.77 | ANPEP (0.46) | MTTPRORC | |
| SCHEMBL4450971 | 0.77 | TACR3 (0.52) | TACR3MTTP | |
| SCHEMBL4450969 | 0.77 | TACR3 (0.52) | TACR3MTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| WO-2008141446-A1 | AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | TACR1 541/4885TACR3 556/4885ULK1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.